1. ALLA AKTIER
  2. NYHETER
  3. SYNACT PHARMA

SynAct Pharma

Nyheter SynAct Pharma Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Change in number of shares and votes in SynAct Pharma AB

LHFI

SynAct Pharma AB (the "Company") announces that the number of shares and votes has increased by 5,191,003 as a result of the directed share issues resolved upon by the extraordinary general meeting on 13 December 2024.

Today, the last trading day of the month, the total number of shares and votes in the Company amounts to 46,487,467.

For further information, please contact:
Jeppe Øvlesen, CEO SynAct Pharma
Tel: +45 2844 7567
Email: JOO@synactpharma.com 

About SynAct Pharma AB
SynAct Pharma AB (publ) (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on resolving inflammation through selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and anti-inflammatory activity in autoimmune and inflammatory diseases to help patients achieve immune balance and overcome their inflammation. For more information: www.synactpharma.com.

This information is information that SynAct Pharma is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2024-12-30 18:45 CET.

Attachments
Change in number of shares and votes in SynAct Pharma AB

Datum 2024-12-30, kl 18:45
Källa MFN
Bifogade filer
Change in number of shares and votes in SynAct Pharma AB